Lite Strategy, Inc. (LITS)
NASDAQ: LITS · Real-Time Price · USD
2.800
+0.090 (3.32%)
Sep 19, 2025, 4:00 PM EDT - Market closed
Company Description
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors.
It also engages in digital asset treasury management. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025.
Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Lite Strategy, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Justin File |
Contact Details
Address: 9920 Pacific Heights Blvd., Suite 150 San Diego, California 92121 United States | |
| Phone | 858 369 7100 |
| Website | litestrategy.com |
Stock Details
| Ticker Symbol | LITS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001262104 |
Key Executives
| Name | Position |
|---|---|
| Justin File | Chief Executive Officer |
| Justin File | Chief Financial Officer |